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Objective: To compare the safety profiles of intracameral cephalosporins in cataract 
surgery.
Patients and methods: In this controlled trial, 129 patients were randomized to one of four 
groups to receive 1 mg of one of three cephalosporins – cefazolin, cefuroxime, or ceftazidime, 
or normal saline – given intracamerally during cataract surgery. Central endothelial cell density 
(ECD) and retinal center point thickness (CPT) were determined by specular microscopy and 
ocular coherence tomography, respectively, before and at 3 months after surgery.
Results: There were no statistical significant differences in the changes of ECD and CPT 
between eyes receiving intracameral cephalosporin and control.
Conclusion: The use of intracameral cefazolin, cefuroxime, or ceftazidime (1 mg in 
0.1-mL solution) at the time of cataract surgery had no significant effect on ECD and CPT 
postoperatively.
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Introduction
Postoperative endophthalmitis is a serious complication of cataract surgery that 
can lead to loss of sight or even loss of the eye. Peroperative topical application of 
5% povidone–iodine or an antibiotic to the conjunctival sac was commonly used as 
prophylaxis against infection.1 Commensal bacteria could not be totally eliminated 
from the ocular surface and could contaminate the anterior chamber during cataract 
surgery.2–4 Peroperative intracameral application of antibiotics might eliminate bacteria 
that gained access to the anterior chamber. Antibiotics could be infused continuously 
during surgery along with the irrigating solution given either as a variable dose5 or as a 
fixed-dose bolus injection at the end of surgery. Cephalosporins and vancomycin were 
studied extensively in retrospective series and prospective trials providing evidence 
on clinical efficacy of intracameral cephalosporins.6–10 Safety aspects were studied via 
the effects on endothelial cell loss and macular thickening. Intracameral drug toxic-
ity could lead to endothelial cell loss or diffuse into the posterior segment of the eye 
resulting in macular edema. In a nonrandomized trial, Montan et al11 showed the use 
of 1-mg intracameral cefuroxime did not lead to endothelial cell loss. Gupta et al12 also 
showed the same dose of intracameral cefuroxime did not lead to macular thickening. 
The effects of cefazolin and ceftazidime on endothelial cell loss and macular thicken-
ing were not reported in the European clinical studies. In this prospective randomized 
trial, we directly compared the safety profiles of three intracameral cephalosporins – 






This study was approved by the hospital clinical research 
ethics committee. Patients aged 50 years or above with senile 
cataract were recruited from the ophthalmic outpatient clinic 
of the hospital. Only one eye in a patient with bilateral cataract 
would be recruited into this study. At the recruitment visit, a 
comprehensive ocular examination was conducted, followed 
by optical biometry, and central endothelial density and 
central macular thickness measurements. These three mea-
surements were conducted by trained technicians. Patients’ 
steady fixation and cooperation were required for acquisition 
of reliable data. Patients giving a history of intraocular sur-
gery or showing signs of ocular pathologies detected at the 
examination were excluded. Systemic conditions leading to 
exclusion were diabetes mellitus, uncontrolled hypertension, 
and heart or renal failure. Patients who would not consent to 
surgery under local or topical anesthesia were also excluded. 
Written informed consent to the study was obtained from 
those who satisfied inclusion criteria.
Central corneal endothelial cell density (ECD) was 
evaluated by fixed-frame analysis with a noncontact specular 
microscope (NonCon ROBO SP-8000; Konan Inc, Hoyogo, 
Japan). The area selected within each frame included 50 
or more cells to qualify for manual analysis. Photographic 
evaluation of the cell image of the entire frame was also 
conducted. An ECD below 2000 cells/mm2 or the presence 
of corneal guttata led to exclusion. Macular thickness was 
determined using time-domain optical coherence tomography 
(OCT). With the fast macular scan protocol provided with the 
Stratus OCT (Carl Zeiss Meditec, Dublin, CA), six equally 
spaced 6-mm radial scans each consisting of 100 sequential 
measurements were centered on the patient’s fixation point. 
The software averaged the six scans to give the central area 
thickness. The center point thickness (CPT) was adopted as 
another primary outcome variable.
The sample size was calculated to have 80% power to 
detect a 5% significant difference of ECD or CPT between a 
cephalosporin and control. Patients were randomized to the 
operating lists of four participating surgeons. To control for 
variations, the randomization scheme was designed such that 
each surgeon would operate on around 32 eyes, about 8 eyes 
from each treatment group. Surgery was conducted within 
14 days after the recruitment visit. Each surgeon used his 
or her most preferred lens removal and irrigation-  aspiration 
technique, the same ophthalmic viscosurgical device, 
intraocular lens model, and lens delivery system to all eyes 
randomized to his or her surgical list. Intraocular lenses were 
to be implanted into the capsular bag. The use of a capsular 
stain or an intracameral miotic, posterior capsular break with 
or without vitreous presentation into the anterior chamber 
would lead to exclusion. To allow comparison of ultrasound 
energy used in the surgery, the effective phaco time (EPT) 
was calculated by multiplying the total phaco time by the 
average percentage power used. The EPT would be the phaco 
duration if 100% power continuous mode was used.
Three cephalosporins were compared – cefazolin (1-g 
vial; Chung Hwa, Suzhou, China), cefuroxime (750-mg vial, 
Zinacef®; GlaxoSmithKline, Brentford, UK), and ceftazi-
dime (1-g vial, Fortum®; GlaxoSmithKline). Solutions were 
prepared from the powder supplied in vials for intravenous 
use. The powder was first dissolved with normal saline (NS) 
(0.9% NaCl; B Braun, Penang, Malaysia) to a concentration 
of 100 mg/mL in a 10-mL syringe. The solution was further 
diluted to the concentration of 10 mg/mL with NS. Water for 
injection or balanced salt solution (BSS) was not used in the 
process. A hypotonic solution could result from dissolution 
and dilution with water for injection. Precipitations could 
form by mixing cephalosporin with BSS. Solutions were 
discarded 4 h after reconstitution.
The  surgeons  were  supplied  with  a  tuberculin 
syringe containing 1 mg (in 0.1 mL) of one of the three 
  cephalosporins – cefazolin, cefuroxime, and ceftazidime – 
drawn from the diluted drug in the 10-mL syringe, or 0.1 mL 
of NS, which was to be injected into the anterior chamber at 
the end of surgery. The surgeons were masked as to which 
treatment was given until the surgery had been completed 
and patient had left the theater.
A standard topical antibiotic–steroid regime (dex-
amethasone and chloramphenicol) was commenced on 
the first   postoperative day. Patients were seen again at 
1 week, 1 month, and 3 months after operation by a masked 
observer. Central ECD and CPT were measured at 3 months 
(±2 weeks) postoperatively by the same trained technician 
masked to the treatment, previous specular microscopy, 
and OCT data.
The primary outcome variables were changes in ECD 
and CPT. Change in ECD was expressed as a percentage, 
obtained by dividing the difference between postoperative 
and preoperative values by the preoperative value. Similarly, 
the percentage change in CPT was obtained by dividing the 
difference between post- and preoperative thickness by the 
preoperative value. Using a statistical package (SAS version 
9.1; SAS Institute, Cary, NC), the percentage changes in ECD 
and CPT with analysis of variance at an alpha value of 0.05 
and the correlation between change in EPT and improvement 




safety of intracameral cephalosporins
Table 1 List of participating surgeons’ preferences on surgical methods, ophthalmic viscosurgical devices, intraocular lenses, implantation 










Cefazolin Cefuroxime Ceftazidime Normal 
saline
Subtotal
A stop and chop 
single coaxial i&A
Vitrax ii and healon Acrysof sA60AT
Monarch C cartridge
8 9 7 8 32
B stop and chop
Bimanual i&A
VisCoat and ProVisc Tecnis Z9003
emerald C cartridge
8 94 9 7 33
C stop and chop
single coaxial i&A
VisCoat and ProVisc Acrysof sA60AT
Monarch C cartridge
8 8 8 8 32
D stop and chop
Bimanual i&A
VisCoat and ProVisc Acrysof sA60AT
Monarch C cartridge
8 8 8 8 32
subtotal 32 34 32 31 129
Notes:  1irrigating solution: To each 500-mL bottle of balanced salt solution (Alcon Laboratories, Forth Worth, TX), 5 mL of 1:10,000 nonpreserved adrenaline acid 
tartrate (DBL, Mulgrave, Australia) was added; 2Vitrax ii (sodium hyaluronate 30 mg/mL), healon (sodium hyaluronate 10 mg/mL; Abbott Medical Optics, santa Ana, CA), 
VisCoat (sodium hyaluronate 16.5 mg/mL, sodium chrondoitin sulfate 40 mg/mL), ProVisc (sodium hyaluronate 10 mg/mL; Alcon Laboratories); 3Acrysof sA60AT one-piece 
intraocular lenses and Monarch delivery system (Alcon Laboratories), Tecnis Z9003 three-piece intraocular lenses and emerald delivery system (Abbott Medical Optics); 
4One patient in the cefuroxime group withdrew before the final visit.
of the outcome variables with the Bonferroni t tests among 
surgeons were also conducted.
Results
A total of 129 patients, comprising 49 males and 80 females, 
were recruited in this study. Mean age of the patients was 
74.5 years (SD = 7 years). They were randomized to be oper-
ated by one of the four participating surgeons. Details of their 
surgical preferences and the number of patients randomized 
are listed in Table 1. One patient in the cefuroxime group 
withdrew before the final follow-up visit. The four groups 
were comparable with regard to their mean age, biometry 
values, visual acuities, baseline ECD and CPT, and EPT 
(Table 2). The mean preoperative unaided visual acuity was 
0.6 (±0.27) logMAR. There was a mean improvement of 0.25 
(±0.33) logMAR after cataract surgery.
The mean pre- and postoperative ECD were 2546 ± 334 
and 2286 ± 463 cells/mm2, respectively. The mean change 
was −9.9% (±17.1%). The mean pre- and postoperative 
CPTs were 172 ± 31 and 179 ± 40 µm. There was a small 
increase of foveal thickening at around 4.6%. One patient in 
the cefazolin group developed clinical macular edema with a 
drop in visual acuity at the final visit. She required treatment 
with topical nonsteroidal anti-inflammatory agent.
We were unable to detect a statistically significant 
change in ECD (P = 0.74) and CPT (P = 0.36) between 
cephalosporins and control (Table 2). There was no sig-
nificant correlation of changes in CPT and improvement 
in visual acuities after surgery (Pearson correlation = 0.07, 
P = 0.43). Post hoc analysis using the Bonferroni t test 
showed the patients   operated by one surgeon had a higher 
rate of endothelial cell loss (P , 0.0001) than the other three 
surgeons. This accounted for the larger standard deviation for 
postoperative endothelial density (463 cells/mm2) compared 
with the preoperative value (334 cells/mm2). No statistical 
difference was detected between the groups after patients 
operated by the surgeon were excluded from analysis.
Discussion
Effectiveness of intracameral cephalosporins as prophylaxis 
for postoperative endophthalmitis after cataract surgery was 
shown in large case series and randomized trials. Results 
from the European Society of Cataract and Refractive Sur-
geons (ESCRS) multicenter randomized control trial on 
16,211 subjects showed the risk of endophthalmitis could 
be reduced by 4.9-fold with an intracameral   injection of 
cefuroxime.6 Another prospective study conducted in Spain 
involving 13,652 cataract patients concluded the efficacy of 
intracameral cefuroxime in reducing the risk of postoperative 
endophthalmitis.7 The choice of cefuroxime was based on the 
microbiological spectrum in the Swedish series of endophthal-
mitis cases from 1996 to 2000.10 In this series, 55 of 59 strains 
of pathogens isolated were sensitive to cefuroxime. Use of 
cefazolin was described in smaller retrospective case series 
from Spain.8,9 Cefazolin is a first-generation cephalosporin 
that has bactericidal effect against Gram-positive cocci, 
particularly staphylococci. Ceftazidime, a third-generation 
cephalosporin, was used in Sweden following an epidemic 
caused by a Gram-negative bacterium.10 Antibiotics chosen 





from cases of endophthalmitis10 or conjunctival cultures of 
patients undergoing cataract surgery.13 Methicillin-resistant 
staphylococci were resistant to cephalosporins, but not to 
vancomycin. Vancomycin was preferred by some groups for 
intracameral use after cataract surgery.14 The US Centers for 
Disease Control and Prevention cautioned against prophy-
lactic use of vancomycin to reduce the risk of emergence of 
vancomycin-resistant organisms.15
Commercial preparations of cephalosporins for intracam-
eral use had not been available. Solutions were reconstituted 
from the powder supplied for intravenous or intramuscular 
use. The manufacturers recommended the use of water for 
injection for reconstitution.16 For intracameral use, we used 
NS to reconstitute the solutions to avoid hypotonicity, as in 
the majority of clinical studies.9–11,17 In a study on the safety 
of intracameral cefuroxime, Gupta et al12 used BSS as   control. 
We used NS as control in an attempt to differentiate the 
effect between cephalosporins, if such existed, and to avoid 
the confounding effect of a control that was different from 
the diluent. Risk of drug toxicity leading to toxic anterior 
segment syndrome could arise from dilution and dosing 
errors. Lockington et al17 compared two protocols for diluting 
cefuroxime and found errors could arise from using small 
(1.0-mL) syringes. The preparations used in this study were 
reconstituted from 1-g vials of cefazolin and ceftazidime and 
750-mg vials of cefuroxime using 10-mL syringes, avoiding 
incomplete dissolution of drug powder and inaccuracies with 
small syringes. We discarded cephalosporin solutions 4 h 
after reconstitution to avoid possible loss of efficacy, despite 
the manufacturers confirmed compatibility with NS and 
retaining potency more than 12 h after reconstitution.16
In this study design, control for sources of variations 
was addressed. We excluded patients with long axial lengths 
(thin maculae) and any ocular or systemic conditions that 
could lead to postoperative macular edema. In clinical tri-
als comparing effects of phacoemulsification methods or 
irrigating solutions on the cornea, variations arising from 
surgeons could be controlled by limiting the procedure to be 
conducted by a single surgeon.17,18 In this trial, four surgeons 
participated, and the number of eyes randomized to each treat-
ment and control were closely matched for every surgeon, 
even though a perfect 4 × 4 allocation was not achieved. This 
design allowed the differentiation of treatment (drug) effect 
from the surgeon effect through statistical analysis. The mean 
endothelial cell loss of 9.9% in this study compared favorably 
with the results in two recent studies on endothelial cell loss 
in phacoemulsification. Using fortified BSS as irrigating 
solution, the mean cell loss at 2 months was 13.2% (±2%) 
in Lucena’s study19 and 22.9% (±14%) at 3 months in the 
Richard et al study.20 In eyes operated by one participating 
surgeon, the mean cell loss was 19.8%. This value was 
comparable to the mean cell loss by Richard et al.20
There was an inherent variability in the measurement 
of ECD. Variations could be reduced by cell analysis over a 
larger area or with repeated measurements. In practice, the 
area of endothelial cells available for counting was limited by 
magnification and the area brought under focus of the specu-
lar microscope. In this study, 50 or more endothelial cells 
Table 2 effects of intracameral cephalosporins versus normal saline (control) on endothelial cell density and central point thickness
Cefazolin Cefuroxime Ceftazidime Normal saline P1
number of eyes 32 342 32 31 –
Mean ± SD
Age, years 74.0 ± 7.8 73.9 ± 7.4 75.8 ± 6.9 74.2 ± 6.1 0.65
Axial length, mm 23.70 ± 0.98 23.44 ± 0.91 23.42 ± 0.70 23.64 ± 1.16 0.55
Average keratometry, D 44.13 ± 1.55 44.33 ± 1.36 44.04 ± 1.28 43.69 ± 1.30 0.31
Visual acuities, logMAR
Preoperative 0.56 ± 0.22 0.63 ± 0.28 0.64 ± 0.31 0.56 ± 0.25 0.31
Change −0.15 ± 0.28 −0.31 ± 0.35 −0.31 ± 0.30 −0.21 ± 0.36 0.15
effective phaco time, sec 31.0 ± 15.3 28.1 ± 19.2 34.3 ± 17.7 26.7 ± 15.6 0.31
Endothelial cell density, cells/mm2
Preoperative 2555 ± 349 2567 ± 327 2536 ± 385 2528 ± 280 0.97
Postoperative 2352 ± 476 2326 ± 481 2206 ± 455 2257 ± 447 –
Change, % −7.7 ± 18.0 −9.0 ± 17.0 −12.0 ± 18.0 −11.0 ± 15.7 0.74
Central macular thickness, μm
Preoperative 171.9 ± 23.8 174.4 ± 36.0 172.1 ± 32.4 171.8 ± 31.8 0.99
Postoperative 176.8 ± 31.1 178.7 ± 51.5 176.3 ± 32.8 187.1 ± 45.7 –
Change, % 2.9 ± 10.7 2.8 ± 22.4 3.3 ± 13.0 9.9 ± 21.0 0.32
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per frame were accepted for analysis. We did not compare 
the absolute cell loss as Montan et al10 did in their study on 
the safety of intracameral cefuroxime. Anticipating a wide 
range of preoperative cell densities (ranging from 2005 to 
3683 cells/mm2), we analyzed the percentage changes rather 
than the absolute differences between the pre- and postopera-
tive ECD values. The percentage values could convey the 
magnitude of cell loss with regard to the baseline ECD. We 
measured ECD at one single time point, namely at 3 months, 
postoperatively. In a study comparing corneal changes after 
phacoemulsification using fortified BSS versus lactated 
Ringer’s solution, Lucena et al19 observed endothelial cell 
count stabilized after 2 weeks postoperatively. It was less 
likely that the drugs could cause continual endothelial cell 
loss, and these effects could be picked up if the measurements 
were conducted at a later date.
To study the effect on macular thickness, we used CPT 
as our primary outcome variable similar to the study by Kim 
et al.21 No topical nonsteroid anti-inflammatory agent was 
used in the pre- and immediate postoperative stage. This 
could have masked the difference in change of macular 
thickness, if any, between the groups. We were unable to 
detect any statistical difference in CPT between treatment 
and control groups. Our result showed a mean increase of 
4.6% (or 7.0 µm) in CPT in the postoperative period. This 
value concurred with other OCT studies on changes of 
retinal thickness with cataract surgery using Stratus OCT. 
Kurz’s group demonstrated a 6–8-µm increase in CPT at 
8 weeks after microincisional cataract surgery.22 Kim et al 
showed a mean 9-µm increase in CPT at 12 weeks.21 Biró 
et al advocated using the 6-mm perifoveal retinal thick-
ness for a more sensitive measure for detecting macular 
edema.23,24 They showed 5.3% increase in 6-mm perifoveal 
values at 2 months after phacoemulsification. The increase 
was maximal at 1 month and had not resolved at 6 months 
postoperatively.
Conclusion
This study could not detect any statistical difference in 
changes in ECD or CPT between cephalosporins and control. 
The magnitude of endothelial cell loss and macular thick-
ening detected in this study was not in excess of that after 
uneventful cataract surgery, and thus it could not be ascribed 
to the use of any one of the three intracameral cephalosporins. 
Cefazolin, cefuroxime, and ceftazidime could be considered 
safe for intracameral use when 1 mg in 0.1 mL was given 
during cataract surgery.
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